Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Neurosurgery
mi
from
Minneapolis, MN
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Neurosurgery
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
UCLA Neurology Clinic
mi
from
Los Angeles, CA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
UCLA Neurology Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center
mi
from
Sacramento, CA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital Translational Research Center
mi
from
Aurora, CO
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital Translational Research Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital
mi
from
Miami, FL
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Northwestern Out-Patient Neurology Clinic
mi
from
Chicago, IL
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Northwestern Out-Patient Neurology Clinic
mi
from
Chicago, IL
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Charlestown, MA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Charlestown, MA
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
SUNY Stony Brook Clinical Research Center, Department of Neurology
mi
from
East Setauket, NY
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
SUNY Stony Brook Clinical Research Center, Department of Neurology
mi
from
East Setauket, NY
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center and the New York Presbyterian Hospital
mi
from
New York, NY
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center and the New York Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University Medical Arts Building
mi
from
Cincinnati, OH
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University Medical Arts Building
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Ohio State University, Wexner Medical Center, Department of Neurology
mi
from
Columbus, OH
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Ohio State University, Wexner Medical Center, Department of Neurology
mi
from
Columbus, OH
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center, Department of Neurology
mi
from
Pittsburgh, PA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center, Department of Neurology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Clinical Research Center
mi
from
Nashville, TN
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Clinical Research Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University of Utah Department of Neurology
mi
from
Salt Lake City, UT
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University of Utah Department of Neurology
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
University of Virginia Health System, Department of Neurology
mi
from
Charlottesville, VA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
University of Virginia Health System, Department of Neurology
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated:  12/31/1969
Swedish Neuroscience Institute
mi
from
Seattle, WA
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)
Status: Enrolling
Updated: 12/31/1969
Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gainesville, FL
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Wayne, IN
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Altenburg,
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Altenburg,
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Abington, PA
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Abington, PA
Click here to add this to my saved trials
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Xenoscience Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
NEA Baptist Clinical
mi
from
Jonesboro, AR
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
NEA Baptist Clinical
mi
from
Jonesboro, AR
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
California Research Foundation
mi
from
San Diego, CA
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
California Research Foundation
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Indago Research & Health Center, Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
mi
from
Orlando, FL
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
American Health Network
mi
from
Avon, IN
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
American Health Network
mi
from
Avon, IN
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Maine Neurology
mi
from
Scarborough, ME
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Maine Neurology
mi
from
Scarborough, ME
Click here to add this to my saved trials